Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

Somewhere in the body of a patient, a small clump of cells, growing undetected, has begun to form a tumor. It has yet to cause pain or visible symptoms of illness. Several months from now, or perhaps ...

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

Beyond blood cancers, iadademstat is being tested in solid tumors such as small cell lung cancer and neuroendocrine tumors, where it has shown initial signs of activity and safety. Additional trials ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small ...

This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer. Lung cancer is the commonest cancer ...